A real-world, single-center experience and the immediate impact of granulocyte and monocyte adsorption apheresis on generalized pustular psoriasis

Uchida, Hideaki; Kamata, Masahiro; Egawa, Shota; Nagata, Mayumi; Fukaya, Saki; Hayashi, Kotaro; Fukuyasu, Atsuko; Tanaka, Takamitsu; Ishikawa, Takeko; Ohnishi, Takamitsu; Sugiura, Kazumitsu; Tada, Yayoi

doi:10.1016/j.jaad.2022.03.001

Cited by 2 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Laboratory tests revealed normal white blood cell count (6700/μL, normal 3300–8600), low serum albumin level (2.4 g/dL, normal 4.1–5.1), and elevated serum C‐reactive protein level (3.97 mg/dL, normal 0–0.14). He was diagnosed with GPP by an experienced dermatologist in our department 7–10 according to the Japanese guidelines 11 . A new medication had not been initiated before the skin lesions developed, which ruled out the possibility of acute generalized exanthematous pustulosis.…”

Section: Casementioning

confidence: 99%

Expression of interleukin‐36 receptor antagonist in a patient with generalized pustular psoriasis harboring the p.Pro82Leu variant in the IL36RN gene

Mizukawa

Kamata

Shimizu

et al. 2023

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

It has recently been revealed that mutation of the IL36RN gene contributes to the development of generalized pustular psoriasis (GPP). The IL36RN gene encodes interleukin (IL)‐36 receptor antagonist (IL‐36Ra), which has antagonistic roles against IL‐36α, ‐36β, and ‐36γ. Previously, sanger sequencing performed in 62 Chinese GPP patients to identify IL36RN mutations revealed a new variant, c.245C>T (p.Pro82Leu), in a single heterozygous state in a patient with adult‐onset GPP with psoriasis vulgaris. Since this p.Pro82Leu variant was not found in the psoriasis vulgaris or control groups in their study, they speculated that this variant might lead to exacerbated inflammatory responses. Meanwhile, Sorting Intolerant From Tolerant and PolyPhen‐2, pathogenicity prediction tools, predict this variant as tolerated and benign. To date, its pathogenicity is unknown. We experienced a patient with GPP harboring the p.Pro82Leu variant, and investigated mRNA and protein expressions of IL‐36Ra. Polymerase chain reaction conducted on hair follicle samples obtained from the scalp of the patient with GPP harboring the p.Pro82Leu using primers to detect mRNA of exons 2 and 5 in IL36RN demonstrated mRNA expression of IL36RN. Immunohistochemical staining revealed IL‐36Ra expression in the keratinocytes of the patient with GPP harboring the p.Pro82Leu as in those of a GPP patient without the mutation (positive control). Furthermore, quantitative analysis of the immunofluorescent staining by ImageJ revealed that the expression level of IL‐36Ra in the keratinocytes of the patient with GPP harboring p.Pro82Leu was higher than that in the healthy control and not lower than that in the GPP patients without the mutation. Our results indicate no aberrant splicing in this variant. In addition, according to the 1000 Genomes Project, this variant could be a founder mutation. Considering these factors together, this variant is unlikely to be associated with the development of GPP.

show abstract

Section: Casementioning

confidence: 99%